Literature DB >> 17940444

Androgen deficiency, diabetes, and the metabolic syndrome in men.

Rita R Kalyani1, Adrian S Dobs.   

Abstract

PURPOSE OF REVIEW: The burden of androgen deficiency in men with diabetes and the metabolic syndrome has become increasingly apparent in population-based studies. This article focuses on the mechanisms underlying the interdependent relationship between these conditions. RECENT
FINDINGS: Various definitions of hypogonadism, the metabolic syndrome and diabetes have been proposed and are used in the literature. Cross-sectional studies have found that between 20 and 64% of men with diabetes have hypogonadism, with higher prevalence rates found in the elderly. Hypogonadism can be a risk factor for the development of diabetes and the metabolic syndrome through various mechanisms including changes in body composition; androgen receptor polymorphisms; glucose transport; and reduced antioxidant effect. Conversely, diabetes and the metabolic syndrome can be risk factors for hypogonadism through some similar but mostly distinct mechanisms, such as increased body weight; decreased sex hormone binding globulin levels; suppression of gonadotrophin release or Leydig cell testosterone production; cytokine-mediated inhibition of testicular steroid production; and increased aromatase activity contributing to relative estrogen excess.
SUMMARY: The relationship between diabetes, the metabolic syndrome and androgen deficiency is complex. Testosterone supplementation, by either oral or intramuscular routes and through exogenous or endogenous delivery, has a promising role in this population although further clinical trials are needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17940444     DOI: 10.1097/MED.0b013e32814db856

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  45 in total

1.  Differentiation of umbilical cord mesenchymal stem cells into steroidogenic cells in comparison to bone marrow mesenchymal stem cells.

Authors:  X Wei; G Peng; S Zheng; X Wu
Journal:  Cell Prolif       Date:  2012-02-13       Impact factor: 6.831

Review 2.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

3.  Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study.

Authors:  Lillian R Meacham; Charles A Sklar; Suwen Li; Qi Liu; Nora Gimpel; Yutaka Yasui; John A Whitton; Marilyn Stovall; Leslie L Robison; Kevin C Oeffinger
Journal:  Arch Intern Med       Date:  2009-08-10

4.  Androgen-responsive gene database: integrated knowledge on androgen-responsive genes.

Authors:  Mei Jiang; Yunsheng Ma; Congcong Chen; Xuping Fu; Shu Yang; Xia Li; Guohua Yu; Yumin Mao; Yi Xie; Yao Li
Journal:  Mol Endocrinol       Date:  2009-09-17

5.  Metabolic syndrome and urologic diseases.

Authors:  Ilya Gorbachinsky; Haluk Akpinar; Dean G Assimos
Journal:  Rev Urol       Date:  2010

6.  Endogenous testosterone and its relationship to preclinical and clinical measures of cardiovascular disease in the atherosclerosis risk in communities study.

Authors:  Reshmi Srinath; Sherita Hill Golden; Kathryn A Carson; Adrian Dobs
Journal:  J Clin Endocrinol Metab       Date:  2015-01-13       Impact factor: 5.958

7.  The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2.

Authors:  Farid Saad; Louis J Gooren
Journal:  J Obes       Date:  2010-08-10

Review 8.  Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review.

Authors:  Sherita H Golden; Karen A Robinson; Ian Saldanha; Blair Anton; Paul W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  2009-06       Impact factor: 5.958

9.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

10.  Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations.

Authors:  C Wang; E Nieschlag; R Swerdloff; H M Behre; W J Hellstrom; L J Gooren; J M Kaufman; J-J Legros; B Lunenfeld; A Morales; J E Morley; C Schulman; I M Thompson; W Weidner; F C W Wu
Journal:  Eur J Endocrinol       Date:  2008-11       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.